StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NDAT.CN$0.07+0.00%
Fair $0.07+0.0%

NDAT.CN

nDatalyze Corp.

Healthcare / Health Information ServicesCanadian Sec

$0.07

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.07Fund rank 24/100 · Data gapFallback financials|
SA 19/F
F-Score: 2/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-466136.00 · quality 36.0/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years ROE is -1.0%, below the 5% threshold
Thesis & Journal · NDAT.CNLocal privado en este navegador · nDatalyze Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-103.4%

↓

Gross Margin

90.6%

↑

Debt/Equity

N/A

•
52-Week Range$0
$0$0

TradingView lightweight chart

NDAT.CN price, volumen y niveles de valoración

Último $0.070Periodo +0.0%
Fair value: $0.070

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-84.1%

FCF CAGR

—

FCF margin

-27195.8%

FCF / Net income

0.84x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1714.0 · net income $-554476.0 · FCF $-466136.0

2022-FY → 2025-FY

Gross margin

90.6%+36.5% pts

Operating margin

-37220.5%-36943.9% pts

Net margin

-32349.8%-32073.7% pts

FCF margin

-27195.8%-26927.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1714.00$1714.00$96342.00$171215.00$424928.00
Net Income$-554476.00$-554476.00$-433075.00$-1.2M$-1.2M
EBITDA$-635995.00$-635995.00$-429235.00$-1.2M$-1.2M
EPS-0.01-0.01—-0.03-0.03
Gross Margin90.6%90.6%69.9%26.2%54.1%
Operating Margin-37220.5%-37220.5%-472.7%-728.7%-276.6%
Net Margin-32349.8%-32349.8%-449.5%-719.6%-276.2%
Balance Sheet
Current Ratio22.2422.24———
Cash Flow
Free Cash Flow$-466136.00$-466136.00$-221638.00$-1.0M$-1.1M
Returns
ROE-103.4%-103.4%-51.6%-215.1%-72.0%
Valuation
P/B5.465.466.4813.465.84
Growth & Yield
Revenue Growth-98.2%-98.2%-43.7%-59.7%—
EPS Growth———0.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +366.7%

Total return

+366.7%

Start / end P/E

n/dx → n/dx

EPS bridge

n/d → -0.01

Residual

+366.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+366.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.